Metformin for Longevity in Non-Diabetics: Where the TAME Trial and the Evidence Stand in 2026

A Decades-Old Diabetes Drug Pitched as the First Anti-Aging Treatment

Metformin has been used for type 2 diabetes for decades, is inexpensive as a generic, and is one of the most prescribed drugs in the world. That track record is why aging researchers chose it for TAME—Targeting Aging with Metformin—a trial designed to test whether a drug can delay the onset of several age-related diseases at once, rather than just one.

The design, described by Nir Barzilai and colleagues in Cell Metabolism in 2016, called for roughly 3,000 adults aged 65 to 79 without diabetes, followed across multiple US centers. The outcome is not lifespan itself but time to a composite of major age-related events: cardiovascular disease, cancer, dementia, and death. Part of the goal is regulatory: to show that "aging" can be targeted with a defined clinical endpoint.

The underlying question is simple to state and hard to answer. Metformin clearly does things in cells—it acts on mitochondrial energy metabolism and activates AMPK, an energy-sensing enzyme. Whether that translates into more healthy years for people who don't need it for blood sugar is still unknown.

Where TAME Actually Stands

As of this update, TAME has not published any efficacy or interim outcome data in a peer-reviewed journal. Claims you may see online about "interim results," biomarker improvements, or percentage reductions in age-related disease from TAME are not based on published trial data. No results date can be given with confidence.

So what human evidence exists?

Randomized evidence in people without diabetes is about diabetes prevention, not aging. In the Diabetes Prevention Program (NEJM, 2002), 3,234 adults with elevated blood glucose were randomized to placebo, metformin 850 mg twice daily, or an intensive lifestyle program. Over an average of 2.8 years, metformin reduced the incidence of type 2 diabetes by 31% versus placebo—while the lifestyle program reduced it by 58% and was significantly more effective.

The longevity signal comes from observational studies, and it conflicts. A UK primary-care database study (Bannister et al., 2014) found that people with type 2 diabetes who started on metformin had longer adjusted survival than matched people without diabetes—this is the finding that fueled much of the anti-aging interest. But a Danish national registry study (Keys et al., 2022), including a comparison of twins, found the opposite: starting metformin for type 2 diabetes was associated with higher mortality than in people without diabetes (adjusted incidence rate ratio 1.32), and the authors concluded the earlier survival advantage did not replicate.

Observational data like these cannot separate the effect of the drug from who gets prescribed it. That is exactly why a randomized trial like TAME matters.

The Exercise Blunting Problem

Two randomized trials in older adults, both published in Aging Cell in 2019, are the main reason many researchers urge caution.

• Aerobic training: In a trial of 53 older adults doing 12 weeks of aerobic exercise training (Konopka et al.), metformin attenuated the improvement in whole-body insulin sensitivity and VO2max compared with placebo, and blocked the training-induced increase in muscle mitochondrial respiration. Responses varied widely between individuals.
• Resistance training (MASTERS trial): In 94 healthy adults aged 65 and older doing 14 weeks of progressive resistance training (Walton et al.), those taking metformin 1,700 mg/day gained less lean body mass and thigh muscle than those on placebo. Strength gains trended lower but the difference was not statistically significant.

These are modest-sized trials, and they do not show that metformin makes exercise useless—exercise improved many outcomes in both groups. But they do suggest a trade-off for people who rely on exercise to maintain fitness and muscle as they age. Strategies such as timing doses away from workouts have not been tested in human trials, so there is no evidence-based way to avoid the effect.

Safety Facts From the Prescribing Information

Metformin is a prescription drug, and its US prescribing information (FDA label) lists several points that apply regardless of why it is taken:

• Lactic acidosis (boxed warning): rare but serious. Risk factors include kidney impairment, age 65 or older, iodinated contrast imaging, surgery and other procedures, conditions that reduce oxygen supply, excessive alcohol intake, and liver impairment.
• Kidney function: metformin is contraindicated when eGFR is below 30 mL/min/1.73 m², starting it is not recommended at eGFR 30–45, and kidney function should be assessed before starting and periodically afterward.
• Vitamin B12: metformin can lower B12 levels. In long-term follow-up of the Diabetes Prevention Program, low B12 was more common with metformin than placebo at 5 years (4.3% vs 2.3%), and each year of metformin use was associated with higher odds of B12 deficiency.
• Gastrointestinal effects: diarrhea and nausea are the most commonly reported adverse reactions.

Anyone considering metformin outside of diabetes care should make that decision with a physician who can weigh these factors against their individual risk.

Who Is the Debate Actually About?

TAME enrolled—by design—older adults, because that is where age-related disease risk is highest and any benefit would be easiest to detect. There is no trial evidence of benefit in younger, healthy, physically active people, and that is also the group with the most to lose from blunted exercise adaptations.

People with prediabetes are a different case: there, metformin has randomized evidence for delaying diabetes, though lifestyle change was more effective in the same trial. Whether it is appropriate is a clinical decision, not a longevity experiment.

AMPK "Alternatives": What the Evidence Supports

Because metformin's appeal is often framed around AMPK, people look for other ways to activate it.

• Berberine is a plant compound sold as a supplement. Small trials, mostly in people with metabolic disorders, report glucose-lowering effects, but long-term safety data are limited, gastrointestinal side effects are common, supplement quality varies, and it can interact with medications. Combining it with glucose-lowering drugs should be discussed with a clinician.
• Gynostemma (jiaogulan) is promoted in longevity circles, but human data are very limited.
• Exercise activates AMPK in muscle as a normal part of physiology and has by far the largest evidence base for healthy aging.
• Time-restricted eating has mixed trial results for weight and metabolic markers and is not suitable for everyone.

None of these has been shown to extend human lifespan either. The practical point is that the best-supported habits—regular physical activity, adequate sleep, a balanced diet, and not smoking—don't require waiting for TAME.

The Regulatory Question

Drug regulators approve medicines for specific diseases, not for "aging." TAME's composite endpoint is an attempt to create a template for testing drugs that target shared biology behind multiple diseases. If it eventually shows a benefit, it could open a path for testing other candidates; if it shows none, that would also be informative.

What to Watch

The key things to watch are whether TAME completes enrollment and publishes its prespecified outcomes, and whether further randomized trials clarify the exercise interaction. Until then, metformin for longevity in people without diabetes remains an unproven hypothesis—biologically interesting, but not supported by outcome data.